Expert Solutions in Drug Formulation Development

Expert Solutions to these Challenging Scenarios

Challenge:

 

Client #1 required a common formulation for a family of four compounds that employed a clear, water-based vehicle to increase topical bioavailability.

  

Velesco Solution:

 

  • Within two days, Velesco developed a common formulation applicable to all four compounds to be dosed at three strengths each.
  • All four compound formulations demonstrated significant improvement versus control.
  • Timely delivery of the formulation allowed the client to meet their tight timelines for an animal study.

Challenge:

 

Client #2 had a poorly soluble compound which they needed in a vehicle acceptable for oral, intraperitoneal, and intravenous use.

  

Velesco Solution:

 

  • Within one week, Velesco successfully developed a formulation that met the client's target concentration, was isotonic, well tolerated by the target animal species, and was acceptable for all three routes of administration.
  • The formulation was simple to prepare and demonstrated 2 week stability at ambient storage.

Challenge:

 

Client #3 had a poorly soluble compound which they wanted formulated as a clear solution/microemulsion at high concentration for oral use in tox studies.

  

Velesco Solution:

 

  • Within one day, Velesco developed a formulation that met the client's target concentration, was a lipid-based self-emulsifying drug delivery system (SEDDS), stable for three weeks at ambient storage, and had potential for further development as a soft-gel formulation.
  • Client requested development of additional oil/water microemulsion formulations at high concentration.  Velesco quickly developed two additional formulations to meet these requirements.  The oil/water microemulsion also demonstrated good stability.

Challenge:

Client #4 had a poorly soluble, non-ionizable compound and required a high dose injectable formulation for animal studies.


Velesco Solution:

  • Regular solvent mixtures were unable to achieve the required dose, but the precipitation characteristics suggested nucleation inhibitors may work.
  • A successful non-toxic formulation containing anti-nucleation polymers was developed.
  • A successful animal study was performed.

News and Events

 

Dave Barnes Featured in Pharmoutsourcing article

 

Happy Holidays!

          aaps logo TN

 

 

                     Follow VelescoPharma on Twitter        LinkedIn IN Icon 25px

 

734-527-9125